105 results about "Hiv patients" patented technology

The present invention relates to a nutritional product for HIV patients that are not on Highly Active Antiretroviral Therapy. More specifically the invention relates to a nutritional composition comprising oligosaccharides. This invention also relates to the manufacture of a nutritional supplement for use in HIV patients.

The invention discloses a human immunodeficiency virus (HIV) affinity adsorption column, comprising a column body and at least one activated affinity microsphere located in the column body, wherein the activated affinity microsphere is connected with a human immunodeficiency virus affinity protein, and the affinity protein can be bound with human immunodeficiency virus. The affinity protein comprises a main receptor CD4 molecule, a gp120 antibody, an auxiliary receptor CXC chemokine receptor 4 (CXCR-4) and a CC chemokine receptor 5 (CCR-5). The affinity microsphere may be a glass microsphere with the size of 1mm, a chitosan crosslinking microsphere with the diameter more than 500 microns, or a gluosan microsphere. The human immunodeficiency virus affinity adsorption column disclosed by the invention is applicable for eliminating the human immunodeficiency virus in the blood of HIV patients, and relieving and treating the immunodeficiency syndrome of HIV patients; and compared with the traditional treatment methods, the immunoadsorption column has high safety, good specificity, small toxic or side effects and good operation simplicity.

The invention concerns a method for stimulating intestinal barrier integrity in a patient infected with HIV by administering to said patient composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.

A composite medicine or its medicinal kit for preventing and treating hepatitis B, hepatitis B, hepatitis C, AIDS and tumor features that its contains kurarinol (or kurarinol oxide) and glycyrrhizic acid, or their pharmacological acceptable salts.

The present invention provides modified erythrocytes which comprise viral receptor proteins capable of mediating entry of respective viruses into the modified erythrocytes. The present invention also provides methods of using the modified erythrocytes for the treatment or prevention of viral infections. In one embodiment, the modified erythrocytes of the present invention comprise CD4 and at least one HIV coreceptor, such as CXCR4 or CCR5. The modified erythrocytes, when administered to an HIV patient, bind to the plasma virus and induce the injection of the HIV ribonucleoprotein complex into the cells. The entrapped viral content is either degraded or deactivated within the erythrocytes, or destroyed by erythrophagocytosis.

The present invention is directed to methods and compositions for the treatment of lipodystrophy. The methods contemplate treatment of lipodystrophy in both HIV and non-HIV patients. More specifically, the methods are directed to a combination therapy that employs growth hormone and statins to effect treatment of lipodystrophy.

The invention relates to methods of treating patients infected with human immunodeficiency virus (HIV) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs thereof.

Modified fusion enhanced erythrocytes (or other cell types and synthetic cells) including human viral receptor proteins, human viral coreceptor proteins and viral derived proteins capable of mediating entry of respective viruses into the modified erythrocytes, cells or pseudo-cells and the method of using the fusion enhanced modified erythrocytes, cells or pseudo-cells for the treatment or prevention of viral infections. The fusion enhanced modified erythrocytes comprises CD4 and at least one HIV coreceptor, such as CXCR4 or CCR5 and as well, at least one of cholesterol rafts, fusin, actin, a viral derived protein such as fusion peptide derived from HIV GP120 or HIV GP41 or a shorter protein derived from a long viral protein, such as a portion of HIV derived GP120, or HIV GP41 such as the 23 N-terminal peptide of the HIV-1 gp 41 protein (AVGIGALFLGFLGAAGSTMGARS) called FP23 (Fusion Peptide). These viral-fusion enhanced cells may also be electrostatic charge enhanced through further additions named in this invention. The modified erythrocytes, when administered to an HIV patient, bind to the plasma virus and induce the injection of the HIV ribonucleoprotein complex into the cells. The entrapped viral content is sequestered within said cell for at least the period of time that the cell maintains its outer membrane integrity. The virus is thereafter either degraded or deactivated within the erythrocytes, cells or pseudo-cells, or destroyed by erythrophagocytosis.

The invention discloses a traditional Chinese medicine composition for preventing and treating AIDS and preparation method thereof. The medicament composition is mainly made from the following raw material medicaments of weight proportions of: astragalus 15-20 parts, Ginseng 7-12 parts, Chinese angelica 8-13 parts, wolfberry 9-14 parts, Chinese magnoliavine 7-12 parts, Tuber of Dwarf Lilyturf 7-12 parts, trichosanthes root 8-13 parts, Poria cocos 7-12 parts, licorice 7-12 parts, radix bupleuri 3-8 parts and cimicifuga foetida 3-8 parts. The traditional Chinese medicine composition of the invention has the functions of supplementing center, boosting qi, nourishing blood and nourishing yin; it can not only resist AIDS virus, but also increase the immunization function of patient substantially, and can eliminate the common symptoms of AIDS patients.

The invention relates to a Chinese herbal composition for curing HIV and a preparation method thereof. The Chinese herba composition is prepared by the following raw medicinal materials in parts by weight: 300-400 parts of ginseng, 200-300 parts of pseudo-ginseng, 120-220 parts of radices trichosanthis, 120-220 parts of indigo naturalis, 10-25 parts of cornu bubali, 120-220 parts of Chinese violet, 120-220 parts of earthworm, 100-200 parts of cutch, 10-25 parts of borneol and 120-220 parts of liquorice. The Chinese herba composition in the invention can increase CD4 lymphocyte counting, has certain inhibiting function on HIV virus, has better effect on symptoms such as acratia, low heat, emaciation, cough, slow wit and the like of HIV patients, especially has obvious effect on acratia and cough.

The invention provides a Chinese medicament for treating AIDS, wherein the constituents comprise (by weight ratio): Chinese angelica root 0.6-1.5, astragalus root 1.6-2.5, wolfberry fruit 1.6-2.5, root of large-flowered skullcap 1.6-2.5, root of Chinese trichosannthes 1.6-2.5, kuh-seng 1.6-2.5, cow's gall 0.6-1.5, licorice root 1.6-2.5, rhodiola root 1.6-2.5, ligustrum japonicum 0.6-1.5, capsule of weeping forsythia 1.6-2.5, and Radix Ranunculi Ternati 1.6-2.5.

The invention discloses specificity detection primers of Aids related intestinal tract Megamonas funiformis translocation and application. The sequence of an upstream primer is Meg-F5'-AGTTCCTTCTCTTCGGAGAAC-3', and the sequence of a downstream primer is Meg-R5'-TAAGGAGGTGATCCAGCC-3'; the specificity detection primers have the advantages that the detection is accurate, simple, convenient and rapid, the sensitivity is high, and the specificity is high and have excellent detectability and a wide application prospect; the technology can be widely applied to early stage monitoring before symptom appearance of Aids patient intestinal tract Megamonas funiformis flora translocation, and a scientific basis is provided for formulating the treatment strategy.

An antibacterial Chinese medicine for treating dermatopathy (skin erosion, eczema, etc), gynopathy, toothache, gastralgia, etc is prepared from 6 Chinese-medicinals including agrimony, dandelion herb, wild chrysanthemum flower, etc through mashing, immersing in spirit for 30 days, and filter.

The invention discloses a composite enteral nutrition applicable to AIDS patients. The composite enteral nutrition comprises nutrients such as proteins, fat, carbohydrates, vitamins, minerals and dietary fibers required by human bodies. The nutrition has a good clinical nutritional supporting effect on the AIDS patients, is beneficial to absorption of the AIDS patients and improvement of poor nutrient conditions of the patients compared with a common whole protein type nutrition, and can obviously improve the living quality of the patients; compared with a common nutrient group, the nutrition has the advantages of remarkably improving the nutrient conditions of the patients and lightening the decline of various physical measurement indexes such as weight caused by AIDS; various biochemical indexes of blood of the patients can be remarkably improved, the blood sugar and the blood fat of the patients are adjusted, and the insulin resistance and the lipid metabolism disorder of the patients are lightened; and the intestinal floras of the patients are adjusted, the intestinal barrier function of the patients is protected, diarrhea caused by the flora disorder of the patients is reduced, the immunity of the patients is enhanced, and the opportunistic infections caused by intestinal flora translocation are reduced.

The invention provides a kit and method for detecting genetic mutation of PR regions and RT regions of HIV-1 genes, and particularly discloses method for detecting genetic mutation of PR regions and RT regions of HIV-1 virus pol genes in plasmas of HIV patient, a primer and a kit comprising mixed liquor of the primer. Based on a generation of sequencing platform, the method has the advantages of being multiple in mutation detection sites, high in accuracy and easy in sample acquisition.

The invention provides an establishment method of a HIV patient talaromyces marneffei disease incidence probability prediction model, and belongs to the technical field of disease prediction models. The prediction model is a model based on a random forest algorithm. The method comprises the following steps: selecting and extracting patient information data; performing standardization processing on different batches of source data; establishing a random forest model for predicting the incidence probability of the talaromyces marneffei disease in the HIV patient; the model is tested and evaluated, independent variables with small influences are removed, and an optimized prediction model is obtained. According to the method, the collected patient information data is subjected to unified standardization processing and then input into software, the relation between the independent variable and the dependent variable is established, the obtained model prediction result is more reliable and accurate, and an effective method is provided for predicting the incidence rate of the talaromyces marneffei disease of the HIV patient.

The present invention relates to the use of a CCR5 antagonist in an HIV infected patient to enhance their immune reconstitution and so treat to HIV related opportunistic conditions resulting from the immunocompromised state of the HIV patient. The invention also allows treatment with a CCR5 antagonist of patients having a CXCR4 using viral population since such patients will also benefit from an increase in their CD4 and/or CD8 cell count.

The invention provides a nucleic acid amplification fluorescent quantitation method for detecting and integrating an HIV-1 virus genomes and application thereof. The method comprises the following steps of (1) building a real-time absolute quantitative HIV total DNA method; (2) preparing a standard product used for integrating an HIV genome; using the method in the step (1) for quantification; (3)performing gradient dilution for integrating an HIV standard product; performing nested fluorescence-quantitative PCR for building an HIV integration standard curve; (4) simultaneously preparing an HIV integration standard product and a sample to be tested; installing an Alu-primer-free reference pipe for each sample to be tested; after the PCR operation in the step (3), comparing the amplification result of the same to be tested with the standard curve to obtain the absolute copy number of the sample to be tested, wherein the virus copy number of the sample to be tested before the HIV integration equals to the copy number difference of the Alu primer sample and the Alu-primer-free reference pipes. The method can be used for distinguishing the integrated and non-integrated HIV virus genome; the virus before the specificity detection has very high sensitivity (5 to 10 copy/mul); the technical guarantee is provided for accurately evaluating HAART treatment effect and precisely quantifying the virus storage base in bodies of HIV patients.

The present invention belongs to the field of Chinese medicine technology, and is especially one kind of powdered Chinese medicine for treating AIDS. The powdered Chinese medicine is prepared with seven kinds of Chinese medicinal materials, including musk, realgar, frankincense, gypsum, etc. and through grinding, mixing and other steps. The Chinese medicine has certain curative in treating AIDS.